NCT02233504View on ClinicalTrials.gov

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

October 2, 2017

Conditions
High Risk MDS or AML Patients
Interventions
DRUG

Exjade® (deferasirox, ICL670)

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02233504 - Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox) | Biotech Hunter | Biotech Hunter